ALK and non-small cell lung carcinoma: A total of 4% of all NSCLC cases develop in patients under the age of 40 years and about half have a targetable driver oncogenic mutation, mainly ALK(19%) and epidermal growth factor receptor (EGFR) (32%) [4].